Navigation Links
ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Date:3/3/2008

SACRAMENTO, Calif., March 3 /PRNewswire/ -- ROBODOC, a Curexo Technology Company, and IBM announced today that they have entered into a major patent Cross licensing agreement. The terms of the agreement were not disclosed by either party.

In addition to its current surgical robotics patents, this agreement gives ROBODOC, access to more than 40,000 patents in IBM'S Global Portfolio and particularly, IBM's surgical robotics patents.

Dan Cerutti, IBM's general manager of intellectual property, said, "IBM enjoys a reputation of innovation and invention for technologies related to computer-assisted medicine and surgery. We are pleased to share our innovations in these areas through patent cross licenses, especially with forward-thinking companies such as ROBODOC."

"This agreement provides us with a significant improvement in our freedom of action in the Surgical Robotics and Information Management field. We intend to continue building our own intellectual property portfolio on an on-going basis," commented Dr. Ramesh Trivedi, President and CEO of ROBODOC.

IBM has earned the most U.S. patents for 15 consecutive years. For more information on IBM, please visit http://www.ibm.com.

ROBODOC, a Curexo Technology Company is the United States-based subsidiary of Korea-based Curexo Inc. (KOSDAQ: 060280.KQ). Its main research facility is in the U.S. and it reaches markets throughout the world.

About ROBODOC

ROBODOC, develops, manufactures, and markets a fully automated surgical robotic system for use in orthopaedic surgery. The system includes two components; ORTHODOC, a computer workstation equipped with proprietary software for preoperative surgical planning, and ROBODOC, a computer-controlled surgical robotic assistant for use in hip and knee replacement as well as other orthopaedic procedures. ROBODOC made medical history in 1992 by assisting in a Total Hip Arthroplasty (THA) procedure. Since that time, the ROBODOC system has been used in over 20,000 surgical procedures assisting surgeons around the world. The ROBODOC Surgical Assistance System is currently in its final stage of review and clearance by the FDA.

ROBODOC(R) and ORTHODOC(R) are registered trade marks of Curexo Technology Corporation.
1433 N. Market Blvd., Suite 1, Sacramento, CA 95834

http://www.robodoc.com

Contact: Dr. R.C. Trivedi

President & CEO

ROBODOC(R)

A Curexo Technology Company

916 285 9943 x 527

or

Ms. Sheila Shah

Marketing Communications

ROBODOC(R)

A Curexo Technology Company

916 285 9943 X 510

press@robodoc.com


'/>"/>
SOURCE ROBODOC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... MN and Bethesda, MD (PRWEB) , ... April ... ... Advancing Innovation announce the formation of a unique intellectual property (IP) sharing and ... potential of their most promising inventions. A main component of this effort is ...
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention ... and clinical research aimed at treating diseases and medical conditions. ... Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ... access our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... ... Alisa Wright, founder and CEO of Singota Solutions , has received ... Lafayette, Indiana. , The Distinguished Alumni Award was established in 1984 to honor ... endeavors. , Wright began her career in the pharmaceutical industry with firms such ...
Breaking Biology Technology:
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
Breaking Biology News(10 mins):